Figure 2
Hazard ratios (HR) for major bleeding or major plus clinically relevant nonmajor bleeding (CRNB) and their 95% confidence intervals (CI) in phase 3 trials comparing NOACs with conventional therapy for acute VTE treatment.
Hazard ratios (HR) for major bleeding or major plus clinically relevant nonmajor bleeding (CRNB) and their 95% confidence intervals (CI) in phase 3 trials comparing NOACs with conventional therapy for acute VTE treatment.
